CanSino Biologics Wins China Approval for Td5cp Vaccine Trial in Children Aged 4-5PUBT·Nov 16, 2026 at 10:04 AM06185+0.71%688185-0.71%
Weekly Recap | CANSINOBIO -10.4%, consensus target above spotWeekly Review·Nov 14, 2026 at 05:38 AM06185+0.71%
Weekly Recap | CANSINOBIO +3.81%, most brokers rate it buyWeekly Review·Nov 7, 2026 at 06:19 AM06185+0.71%
Weekly Recap | CANSINOBIO -6.53%, consensus sits at strong buyWeekly Review·Oct 24, 2026 at 05:36 AM06185+0.71%
CanSinoBIO Reports Positive Primary Immunization Data From Phase II Polio Vaccine TrialPUBT·Oct 24, 2026 at 12:34 AM06185+0.71%
Renaming is the easy part. Hong Kong's small caps are learning the hard partGlobal Report·Oct 21, 2026 at 10:51 AM00117+2.34%01937-0.71%
Nobel Prize and Healthcare Reform Converge in Hong Kong's Medical Innovation EcosystemGlobal Report·Oct 21, 2026 at 10:13 AM06185+0.71%02697-5.86%
Dmall's DouBao Surge and Microcap Buybacks Define Hong Kong's Niche Market MovesGlobal Report·Oct 21, 2026 at 09:17 AM01883+0.21%02586-0.90%
Weekly Recap | CANSINOBIO -8.4%, consensus target above spotWeekly Review·Oct 17, 2026 at 06:05 AM06185+0.71%
CanSinoBIO Hosts Annual Scientific Advisory Board Meeting in BelgiumPUBT·Oct 16, 2026 at 10:11 AM06185+0.71%688185-0.71%